Stock Research: Amphastar Pharmaceuticals

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Amphastar Pharmaceuticals

NasdaqGS:AMPH US03209R1032
76
  • Value
    75
  • Growth
    21
  • Safety
    Safety
    67
  • Combined
    56
  • Sentiment
    76
  • 360° View
    360° View
    76
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Amphastar Pharmaceuticals develops, manufactures, markets, and sells biopharmaceutical products. It operates in the biopharmaceutical industry. The company distributes its products primarily through group purchasing organizations and drug wholesalers. In the last fiscal year, the company had a market cap of $1,009 million, profits of $374 million, revenue of $732 million and 2028 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 76 (better than 76% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Amphastar Pharmaceuticals are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Amphastar Pharmaceuticals. The consolidated Value Rank has an attractive rank of 67, which means that the share price of Amphastar Pharmaceuticals is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 67% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 75. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 76. But the consolidated Growth Rank has a low rank of 21, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 79 of its competitors have better growth. ...read more

more
Index
NASDAQ
D.J. US Pharmaceutical
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
67 55 6 45
Growth
21 45 97 93
Safety
Safety
75 74 87 48
Sentiment
76 58 94 92
360° View
360° View
76 66 96 90
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
22 26 26 23
Opinions Change
90 36 79 50
Pro Holdings
n/a 76 98 100
Market Pulse
93 73 78 96
Sentiment
76 58 94 92
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
67 55 6 45
Growth
21 45 97 93
Safety Safety
75 74 87 48
Combined
56 68 81 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
80 83 37 57
Price vs. Earnings (P/E)
55 49 28 56
Price vs. Book (P/B)
57 46 13 44
Dividend Yield
1 1 1 1
Value
67 55 6 45
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
55 28 89 39
Profit Growth
25 50 78 85
Capital Growth
61 90 59 60
Stock Returns
11 19 91 93
Growth
21 45 97 93
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
34 31 68 75
Refinancing
65 56 39 47
Liquidity
77 89 98 30
Safety Safety
75 74 87 48

Similar Stocks

Discover high‑ranked alternatives to Amphastar Pharmaceuticals and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.